Clinical features and natural history of hepatocellular adenomas: The impact of obesity

Alimentary Pharmacology and Therapeutics

Volumn 34, Issue 6, 2011, Pages 664-674

  Bunchorntavakul, C ^a   Bahirwani, R ^a   Drazek, D ^b   Soulen, M C ^b   Siegelman, E S ^b   Furth, E E ^b   Olthoff, K ^b   Shaked, A ^b   Reddy, K R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRACEPTIVE AGENT; SERUM ALBUMIN;

ADOLESCENT; ADULT; ARTIFICIAL EMBOLISM; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; FATTY LIVER; FEMALE; FOLLOW UP; HEPATOCELLULAR ADENOMA; HUMAN; HYPERTENSION; LIVER ADENOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; METABOLIC SYNDROME X; MULTIPLE CANCER; OBESITY; PRIORITY JOURNAL; REVIEW; TUMOR VOLUME;

ADENOMA, LIVER CELL; ADOLESCENT; ADULT; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 80052027303     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2011.04772.x     Document Type: Review

References (46)

1. van der Windt DJ, Kok NF, Hussain SM, et al. Case-orientated approach to the management of hepatocellular adenoma. Br J Surg 2006; 93: 1495-502. (Pubitemid 44893651)
2. Deneve JL, Pawlik TM, Cunningham S, et al. Liver cell adenoma: a multicenter analysis of risk factors for rupture and malignancy. Ann Surg Oncol 2009; 16: 640-8.
3. Dokmak S, Paradis V, Vilgrain V, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009; 137: 1698-705.
4. Reddy KR, Kligerman S, Levi J, et al. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg 2001; 67: 173-8. (Pubitemid 33738212)
5. Edmondson HA, Henderson B, Benton B,. Liver-cell adenomas associated with use of oral contraceptives. N Engl J Med 1976; 294: 470-2.
6. Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma. The role of oral contraceptive use. JAMA 1979; 242: 644-8. (Pubitemid 9252465)
7. Shaked O, Siegelman ES, Olthoff K, Reddy KR,. Benign solid and cystic lesions of the liver: a multidisciplinary approach. Clin Gastroenterol Hepatol 2011; 9: 547-62.
8. Kawakatsu M, Vilgrain V, Belghiti J, Flejou JF, Nahum H,. Association of multiple liver cell adenomas with spontaneous intrahepatic portohepatic shunt. Abdom Imaging 1994; 19: 438-40. (Pubitemid 24267898)
9. Brunt EM, Wolverson MK, Di Bisceglie AM,. Benign hepatocellular tumors (adenomatosis) in nonalcoholic steatohepatitis: a case report. Semin Liver Dis 2005; 25: 230-6. (Pubitemid 40781075)
10. Paradis V, Champault A, Ronot M, et al. Telangiectatic adenoma: an entity associated with increased body mass index and inflammation. Hepatology 2007; 46: 140-6. (Pubitemid 47171930)
11. Furlan A, van der Windt DJ, Nalesnik MA, et al. Multiple hepatic adenomas associated with liver steatosis at CT and MRI: a case-control study. AJR Am J Roentgenol 2008; 191: 1430-5.
12. Wolin KY, Carson K, Colditz GA,. Obesity and cancer. Oncologist 2010; 15: 556-65.
13. Bioulac-Sage P, Laumonier H, Couchy G, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50: 481-9.
14. Vetelainen R, Erdogan D, de Graaf W, et al. Liver adenomatosis: re-evaluation of aetiology and management. Liver Int 2008; 28: 499-508. (Pubitemid 351411136)
15. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003; 38: 420-7. (Pubitemid 36919863)
16. Marchesini G, Marzocchi R,. Metabolic syndrome and NASH. Clin Liver Dis 2007; 11: 105-17. (Pubitemid 46829976)
17. Mottillo S, Filion KB, Genest J, et al. The metabolic syndrome and cardiovascular risk a systematic review and meta-analysis. J Am Coll Cardiol 2010; 56: 1113-32.
18. Stickel F, Hellerbrand C,. Non-alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut 2010; 59: 1303-7.
19. Farges O, Ferreira N, Dokmak S, Belghiti J, Bedossa P, Paradis V,. Changing trends in malignant transformation of hepatocellular adenoma. Gut 2011; 60: 85-9.
20. Sanyal AJ, Banas C, Sargeant C, et al. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006; 43: 682-9.
21. Kawada N, Imanaka K, Kawaguchi T, et al. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009; 44: 1190-4.
22. Takuma Y, Nouso K,. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010; 16: 1436-41.
23. Grazioli L, Morana G, Kirchin MA, Schneider G,. Accurate differentiation of focal nodular hyperplasia from hepatic adenoma at gadobenate dimeglumine-enhanced MR imaging: prospective study. Radiology 2005; 236: 166-77. (Pubitemid 40853309)
24. Brancatelli G, Federle MP, Vullierme MP, Lagalla R, Midiri M, Vilgrain V,. CT and MR imaging evaluation of hepatic adenoma. J Comput Assist Tomogr 2006; 30: 745-50. (Pubitemid 44368210)
25. Paradis V, Benzekri A, Dargere D, et al. Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. Gastroenterology 2004; 126: 1323-9. (Pubitemid 38559002)
26. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
27. Baum JK, Bookstein JJ, Holtz F, Klein EW,. Possible association between benign hepatomas and oral contraceptives. Lancet 1973; 2: 926-9.
28. Heinemann LA, Weimann A, Gerken G, Thiel C, Schlaud M, DoMinh T,. Modern oral contraceptive use and benign liver tumors: the German Benign Liver Tumor Case-Control Study. Eur J Contracept Reprod Health Care 1998; 3: 194-200. (Pubitemid 128690547)
29. Flegal KM, Carroll MD, Ogden CL, Curtin LR,. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303: 235-41.
30. Centers for Disease Control and Prevention: U.S. Obesity Trends. Available at:. Accessed January 24, 2011.
31. Gallo MF, Lopez LM, Grimes DA, Schulz KF, Helmerhorst FM,. Combination contraceptives: effects on weight. Cochrane Database Syst Rev 2008; 4: CD003987.
32. Higginbotham S,. Contraceptive considerations in obese women: release date 1 September 2009, SFP Guideline 20091. Contraception 2009; 80: 583-90.
33. Belghiti J, Hiramatsu K, Benoist S, Massault P, Sauvanet A, Farges O,. Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 2000; 191: 38-46. (Pubitemid 30439557)
34. Kooby DA, Fong Y, Suriawinata A, et al. Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 2003; 7: 1034-44. (Pubitemid 37524071)
35. Kapp N, Curtis KM,. Hormonal contraceptive use among women with liver tumors: a systematic review. Contraception 2009; 80: 387-90.
36. Ramseur WL, Cooper MR,. Asymptomatic liver cell adenomas. Another case of resolution after discontinuation of oral contraceptive use. JAMA 1978; 239: 1647-8. (Pubitemid 8317748)
37. Gordon SC, Reddy KR, Livingstone AS, Jeffers LJ, Schiff ER,. Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med 1986; 105: 547-9. (Pubitemid 16003997)
38. Siegel AB, Zhu AX,. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009; 115: 5651-61.
39. Starley BQ, Calcagno CJ, Harrison SA,. Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. Hepatology 2010; 51: 1820-32.
40. Tanaka S, Mohr L, Schmidt EV, Sugimachi K, Wands JR,. Biological effects of human insulin receptor substrate-1 overexpression in hepatocytes. Hepatology 1997; 26: 598-604. (Pubitemid 27392349)
41. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO,. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 2004; 89: 2745-9. (Pubitemid 38766360)
42. Glintborg D, Andersen M,. An update on the pathogenesis, inflammation, and metabolism in hirsutism and polycystic ovary syndrome. Gynecol Endocrinol 2010; 26: 281-96.
43. Wake DJ, Strand M, Rask E, et al. Intra-adipose sex steroid metabolism and body fat distribution in idiopathic human obesity. Clin Endocrinol (Oxf) 2007; 66: 440-6. (Pubitemid 46239306)
44. Bioulac-Sage P, Laumonier H, Laurent C, Zucman-Rossi J, Balabaud C,. Hepatocellular adenoma: what is new in 2008. Hepatol Int 2008; 2: 316-21.
45. Erdogan D, van Delden OM, Busch OR, Gouma DJ, van Gulik TM,. Selective transcatheter arterial embolization for treatment of bleeding complications or reduction of tumor mass of hepatocellular adenomas. Cardiovasc Intervent Radiol 2007; 30: 1252-8. (Pubitemid 350059824)
46. Kobayashi S, Sakaguchi H, Takatsuka M, et al. Two cases of hepatocellular adenomatosis treated with transcatheter arterial embolization. Hepatol Int 2009; 3: 416-20.